$-0.06 EPS Expected for BioPharmX (BPMX); Nuveen California Municipal Value Fund (NCA)’s Sentiment Is 1.63

December 6, 2017 - By Ellis Scott

The stock increased 0.48% or $0.05 during the last trading session, reaching $10.51. About 57,614 shares traded or 58.93% up from the average. Nuveen California Municipal Value Fund, Inc. (NCA) has declined 5.82% since December 6, 2016 and is downtrending. It has underperformed by 22.52% the S&P500.

Analysts expect BioPharmX Corporation (NYSEAMERICAN:BPMX) to report $-0.06 EPS on December, 12.They anticipate $0.07 EPS change or 53.85% from last quarter’s $-0.13 EPS. After having $-0.06 EPS previously, BioPharmX Corporation’s analysts see 0.00% EPS growth. The stock decreased 2.50% or $0.003 during the last trading session, reaching $0.1169. About 2.78M shares traded or 40.17% up from the average. BioPharmX Corporation (NYSEAMERICAN:BPMX) has declined 5.75% since December 6, 2016 and is downtrending. It has underperformed by 22.45% the S&P500.




First Foundation Advisors holds 0.13% of its portfolio in Nuveen California Municipal Value Fund, Inc. for 220,635 shares. Paragon Capital Management Ltd owns 10,000 shares or 0.05% of their US portfolio. Moreover, Clenar Muke Llc has 0.03% invested in the company for 53,796 shares. The California-based Gemmer Asset Management Llc has invested 0.02% in the stock. Stratos Wealth Partners Ltd., a Ohio-based fund reported 29,600 shares.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter products that address dermatology and womenÂ’s health markets. The company has market cap of $14.61 million. The firm offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). It currently has negative earnings. The Company’s clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.